Topical Hydromorphone for Wound Healing
Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Wound Healing
Intervention: hydromorphone (Drug)
Phase: Phase 1/Phase 2
Sponsored by: Hordinsky, Maria K., MD
Official(s) and/or principal investigator(s):
Maria Hordinsky, MD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute
Robert Hebbel, MD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute
The hypothesis is that topical opioids will hasten wound healing in humans.
Official title: Topical Hydromorphone for Wound Healing
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: Healing rates and microvessel density will be compared statistically for the control-ointment versus hydromorphone-ointment subjects.
This is based on our published data that morphine is a powerful stimulant of angiogenesis
and our preclinical study of wounds in rats which demonstrate that topical opioids
(morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study
will focus on hydromorphone which was more powerful than morphine as a wound-healer in the
Minimum age: 18 Years.
Maximum age: 65 Years.
- Self-identified as normal, healthy volunteers age 18-65.
- Known bleeding disorder.
Locations and Contacts
University of Minnesota, Minneapolis, Minnesota 55455, United States
Starting date: October 2003
Last updated: February 26, 2010